A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC704865, IND7921) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC683864, IND61010) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Trial Profile

A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC704865, IND7921) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC683864, IND61010) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Sep 2013 Planned end date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Dec 2009 New source identified and integrated (Memorial Sloan-Kettering Cancer Center 08-157)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top